Robert Livingston
University of Arizona
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Livingston as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01394211 · Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast CancerUniversity of Arizona · terminated · Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer · principal investigator
- N/ANCT01385280 · Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerUniversity of Arizona · completed · Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical ResearchP30CA023074 · NCI · UNIVERSITY OF ARIZONA · fiscal years 2009 to 2013 · $349,659 awarded in 2013Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:11 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.N Engl J Med · 20031,384 citationsRCR 30.7
- 1,176 citationsRCR 22.2
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.J Natl Cancer Inst · 2005835 citationsRCR 17.9
- Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.J Clin Oncol · 2014513 citationsRCR 14.3
- Combination anastrozole and fulvestrant in metastatic breast cancer.N Engl J Med · 2012292 citationsRCR 7.4
- Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.N Engl J Med · 2010266 citationsRCR 6.3
- Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.Cancer · 2000204 citationsRCR 6.4
- 197 citationsRCR 3.9
- 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol · 2001151 citationsRCR 4.2
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.J Clin Oncol · 2008139 citationsRCR 2.7